Deal Tracker · Countries

United States pharma deals

26 pharma deals involving United States — companies based there or deals covering the market — tracked by EPT: licensing, distribution & partnerships. Most active: Gilead Sciences, Abbott, Hikma Pharmaceuticals & Mubadala Bio. Latest: Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).

26
deals tracked
24
announced in 2026
$293m
disclosed value (2 deals)
35%
licensing, the top deal type
  • EPT has tracked 26 United States pharma deals (2021–2026), 24 of them announced in 2026.
  • The most common structures are licensing (35%), distribution (27%) & partnerships (15%).
  • Values were disclosed for 2 of 26 deals, totalling $293m; the largest is Ocugen → Roots Pharmaceutical ($259m, 14 Oct 2026).
  • The most active companies: Gilead Sciences (3), Abbott (2), Hikma Pharmaceuticals (2) & Mubadala Bio (2).

Most active companies

Gilead Sciences (3) · Abbott (2) · Hikma Pharmaceuticals (2) · Mubadala Bio (2) · SPIMACO (2) · Viatris (2)

Countries involved

Saudi Arabia (7) · UAE (6) · Egypt (2) · Kuwait (2) · Algeria (1) · Azerbaijan (1)

Largest disclosed deals

Questions

How many United States pharma deals has EPT tracked?
26 as of 16 Nov 2026, covering 2021–2026; 24 were announced in 2026. The most recent is Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).
What types of United States pharma deals are most common?
Licensing: 9 (35%); Distribution: 7 (27%); Partnership / Collaboration: 4 (15%); Supply / Manufacturing: 2 (8%).
Which companies are most active in United States pharma deals?
Gilead Sciences (3 deals), Abbott (2 deals), Hikma Pharmaceuticals (2 deals), Mubadala Bio (2 deals), SPIMACO (2 deals), Viatris (2 deals).
What is the largest disclosed United States pharma deal?
Ocugen → Roots Pharmaceutical: $259m (Licensing, 14 Oct 2026); Hanmi Pharmaceutical → Organon: $34m (Distribution, 21 May 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)